基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 抑制剂 酪氨酸蛋白激酶/信号转导子和转录活化子抑制剂(JAK/STAT) JAK 抑制剂 巴瑞克替尼 巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050
  • 巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050-abs810404
  • 巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050-abs810404

1/2

巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050-abs810404

现货
Baricitinib
¥55 5mg 起订
¥85 10mg 起订
¥245 50mg 起订
¥415 100mg 起订
上海 更新日期:2026-11-17

爱必信(上海)生物科技有限公司

VIP7年

科技型中小企业

高新技术企业

联系人:爱必信
手机:13761418683 拨打
邮箱:fengmj@univ-bio.com

产品详情:

中文名称:
巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050
英文名称:
Baricitinib
CAS号:
1187594-09-7
品牌:
Absin
纯度规格:
<p>>98%</p>
产品类别:
其它
货号:
abs810404
一、产品概述

巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050 是来自Absin品牌的高品质产品,适用于科研实验领域。

更多产品描述请查看优宁维旗下爱必信官网(https://www.absin.cn/baricitinib/abs810404.html?mk_channel=chemicalbook)

二、产品信息
货号abs810404
SKU货号abs810404-5mg
品牌Absin
中文名称巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050
英文名称Baricitinib
CAS号1187594-09-7
纯度

>98%

分子量371.42
可溶性DMSO : 69 mg/mL (185.8 mM)
外观White or off-white solid
抗原名称JAK2 ,JAK1 ,TYK2 ,JAK3
商品描述

Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Phase 3.

In vitro(体外研究)
Baricitinib inhibits IL-6–stimulated phosphorylation of the canonical substrate STAT3 (pSTAT3) and subsequent production of the chemokine MCP-1 with IC50 values of 44 nM and 40 nM, respectively, in PBMCs. Baricitinib also inhibits pSTAT3 stimulated by IL-23 with IC50 od 20 nM in isolated naive T-cells.
In vivo(体内研究)
Baricitinib inhibits IL-6–stimulated phosphorylation of STAT3 in whole blood with an IC50 of 128 nM. Baricitinib (10 mg/kg p.o.) is expected to inhibit JAK1/2 signaling (by ≥50%) in rats for about 8 hours. Baricitinib (10 mg/mL, p.o.) inhibits disease scores in dose-dependent manner in rats with established disease in the adjuvant arthritis model. Baricitinib treatment, compared with vehicle, inhibits the increase in hind paw volumes during the 2 weeks of treatment by 50% at a dose of 1 mg/kg and >95% at doses of 3 mg/kg or 10 mg/kg. Baricitinib treatment, compared with vehicle, also inhibits composite score of immune infiltrate, edema, and periarticular tissue appearance by 27% at a dose of 1 mg/kg, 64% at doses of 3 mg/kg and 82% at doses of 10 mg/kg in rats with established disease in the adjuvant arthritis model. Baricitinib reduces bone resorption by 15%, 61%, and 67% with increasing dose level (1, 3, and 10 mg/kg) in rats with established disease in the adjuvant arthritis model. Baricitinib (10 mg/kg, daily for 2 wk, p.o.) results in radiographic improvements with restoration of the normal architecture and appearance to the ankle and tarsals in rats with established disease in the adjuvant arthritis model. Baricitinib reduces levels of pSTAT3 in a dose- and time-dependent manner in the peripheral blood of rAIA animals. Baricitinib (10 mg/mL, p.o.) improves a composite score of joint damage by 47% in the murine CIA model. Baricitinib (10 mg/kg) reduces pannus (74%) and bone damage (78%) and improves cartilage damage (43%) and signs of inflammation (33%), resulting in a 53% improvement in an aggregate score of disease in the collagen Ab-induced arthritis (CAIA) murine model. Baricitinib (10 mg/kg) inhibits the delayed-type hypersensitivity response by 48% in both the CIA and CAIA models. Baricitinib is efficacious in active rheumatoid arthritis patients refractory to disease modifying drugs and biologics. Baricitinib preferentially inhibits JAK1 and JAK2, with 10-fold selectivity over Tyk2 and 100-fold over JAK3. The observed effects of GLPG-0634 on the ACR20, albeit in a smaller study, appear to be at least as good as that seen with tofacitinib and superior to that of baricitinib, since baricitinib only moderately affect the ACR20 values in Phase IIa clinical studies. Baricitinib has the dose-limiting side-effect of inducing anaemia which has been attributed to its effects on JAK2 but has clearly shown efficacy.
三、背景
别名巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050
CAS号1187594-09-7
四、制备和贮存
保存方式Store at -20℃ for three years(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
五、产品特点
  • 品质保证:经过严格的质量控制,确保产品的高品质和稳定性。
  • 高纯度:纯度达到<p>>98%</p>。
六、注意事项
  • 本产品仅供科学研究使用,不可用于临床诊断或治疗。
  • 请在通风良好的环境下操作,佩戴适当的个人防护装备。
  • 如不慎接触皮肤或眼睛,请立即用大量清水冲洗并就医。
巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050

公司简介

爱必信是优宁维生物旗下自主品牌,是一家从事生物学试剂及耗材的高新技术企业。公司秉承“为生命科学创造便利!为客户创造价值!为员工创造幸福人生!”的发展理念,拥有专业的产品研发质检团队、市场营销团队及先进仓储物流等管理团队。荣获2021年度上海市“专精特新”企业称号。 主要经营产品有:生化试剂(常用生化试剂、生物学实验常用试剂、荧光染料、激动剂/抑制剂,植物提取物)、细胞生物学(细胞培养产品、血清、基质胶、添加剂、检测试剂盒)、免疫学产品、分子生物学产品、实验室仪器/耗材、产品定制和检测服务。 Absin还提供一些独有的特色产品:霍乱毒素B亚单位(CTB)、 鸡胚提取物(CEE)、 牛脑垂体提取物、 呼吸爆发试剂盒、 多色免疫组化试剂盒、 mRNA原料等在业界深受客户喜欢。 Absin秉承踏实,务实,求精和不断创新的精神为中国科学家提供优质产品,努力打造属于中国自己的生物试剂品牌,为广大科学家提供更全面更丰富更优质的产品。 爱科研,必信它(Absin)! Absin-生命科学百宝箱∑! 欢迎访问我们网站:www.absin.cn, 更多产品、更多便利,就在你身边!

成立日期 (16年)
注册资本 2500万
员工人数 100-500人
年营业额 ¥ 1000万-5000万
经营模式 工厂,试剂,定制,服务
主营行业 生化试剂,抗体,分子生物学,生物活性小分子

巴瑞克替尼;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104; INCB-028050相关厂家报价 更多

  • 巴瑞替尼
  • 巴瑞替尼
  • 广州隽沐生物科技股份有限公司 VIP
  • 2026-11-17
  • 询价
内容声明
拨打电话 立即询价